FXI-directed strategies
| FXI inhibitor class . | Compounds . | Mechanisms of action . | Administration . | Onset/offset . |
|---|---|---|---|---|
| Antisense oligonucleotide | IONIS-416858 | Reduces hepatic synthesis of FXI by inducing catalytic degradation of FXI messenger RNA | Parenteral | Slow onset and offset |
| Monoclonal antibodies | BAY1213790, BAY1831865, MAA868 | Suppress FXIa generation and/or inhibit FXIa activity | Parenteral | Rapid onset and slow offset |
| Aptamers | 11.16, 12.7 | Bind to FXI and/or FXIa and block its activity | Parenteral | Rapid onset and likely rapid offset |
| Small molecules | BMS-986177, EP-7041, ONO-5450598 | Bind to the catalytic domain of FXIa | Oral or parenteral | Rapid onset and likely rapid offset |
| FXI inhibitor class . | Compounds . | Mechanisms of action . | Administration . | Onset/offset . |
|---|---|---|---|---|
| Antisense oligonucleotide | IONIS-416858 | Reduces hepatic synthesis of FXI by inducing catalytic degradation of FXI messenger RNA | Parenteral | Slow onset and offset |
| Monoclonal antibodies | BAY1213790, BAY1831865, MAA868 | Suppress FXIa generation and/or inhibit FXIa activity | Parenteral | Rapid onset and slow offset |
| Aptamers | 11.16, 12.7 | Bind to FXI and/or FXIa and block its activity | Parenteral | Rapid onset and likely rapid offset |
| Small molecules | BMS-986177, EP-7041, ONO-5450598 | Bind to the catalytic domain of FXIa | Oral or parenteral | Rapid onset and likely rapid offset |
Adapted from Raskob et al.2